FDA discards depression drug ALKS 5461 of Alkermes The FDA has rejected approval for ALKS 5461 of Alkermes in major depressive disorder. ALKS 5461 is a fixed-dose combination of buprenorphine and s...
Voyager clears Neurocrine agreement for Parkinson's gene therapy Voyager Therapeutics is signing a collaboration agreement with Neurocrine Biosciences that will remunerate the Cambridge, Massachusetts-based biotech USD 165 million upfront. In return, Neurocrine benefits certain rights to four gene therapy progra...
Find MoreBiodesix collaborates with MRM for development of mass-spec proteomics Biodesix, the lung cancer diagnostic developer is collaborating with MRM Proteomics to authorize its iMALDI automated assay technology for quantifying proteins using mass spectrometry. It is done with the goal of enabling precision therapies....
Find MoreBridgeBio bags USD 299 Million for genetic diseases BridgeBio Pharma has received a USD299.2 million for its progress in genetic disease pipeline. This includes assets in preclinical and clinical development. Several therapeutic areas are being taken under the consideration of the pharma. Also, th...
Find MoreStopping breast cancer metastasis by killing tumor cells in their sleep Oncology researchers believed that dormant breast cancer cells are not responsive to chemotherapy. But these inactive cancer cells can be active at any time and cause life-threatening metastases. Scientists at the Fred Hutchinson Cancer Rese...
Find MoreAnti-aging startup Juvenescence raises USD 46 Million Juvenescence has bagged the USD 46 million in series B financing. The investment tees the anti-ageing startup to progress the multi-asset pipeline. Jim Mellon, a British billionaire biotech investor, created Juvenescence with early Medivation backer Greg Bai...
Find MoreAbbott’s pea-sized implant for congenital heart defects gets FDA approval FDA approved Abbott for its Amplatzer Piccolo Occluder, the implant designed for premature babies. The device is used to treat patent ductus arteriosus (PDA), a life-threatening opening in the hearts of premature newborns and is a minimal...
Find MoreApollomics raises USD 100 Million for funding of transpacific cancer R&D plan Apollomics has raised USD 100 million for funding an oncology clinical trial program. The series B round sets Apollomics to progress its c-Met inhibitor and pipeline of other clinical-phase assets. OrbiMed Asia-backed Apo...
Find MoreThe oral depression drug of Sage Therapeutics meets phase 3 efficacy A phase 3 trial of oral treatment of Sage Therapeutics for postpartum depression (PPD) has hit its primary endpoint. The drug, SAGE-217, showed significant improvements on a depression score and saw no fainting cases. SAGE-217 is an a...
Find MoreAtlas Venture raises USD 250 Million for investing in later-stage Massachusetts-based Atlas Venture has raised USD 250 million for later-stage investments. The fund will allow the VC shop to bolster its startups through series B and beyond. The early-stage operation has bolstered a couple of startups like P...
Find MoreDoctors and scientists have recognized that traditional, complementary and alternative therapies hav.....
Find MoreUS Cancer Statistics show that more than half a million suffer from this disease, which is the secon.....
Find MoreDry Age-related Macular Degeneration (Dry AMD), also called atrophic AMD, is the most common form of.....
Find MoreCocaine Use Disorder (CUD) is characterized as a substance use disorder in which biological, psychol.....
Find MoreT cell Lymphoma (TCL) is cancer that develops in the T-lymphocytes. T-cell Lymphomas are majorly cla.....
Find MoreThe medical device industry is experiencing rapid change as innovation is accelerating, new business.....
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.